Literature DB >> 17662091

IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Sofie Haglund1, Jan Taipalensuu, Curt Peterson, Sven Almer.   

Abstract

AIMS: Azathioprine and 6-mercaptopurine are steroid-sparing drugs used in inflammatory bowel disease (IBD). The polymorphic enzyme thiopurine S-methyltransferase (TPMT) is of importance for thiopurine metabolism and occurrence of adverse events. The role of other thiopurine-metabolizing enzymes is less well known. This study investigated the role of inosine-5'-monophosphate dehydrogenase (IMPDH), which is a key enzyme in the de novo synthesis of guanine nucleotides and also strategically positioned in the metabolic pathway of thiopurines.
METHODS: IMPDH was measured in 100 healthy blood donors. IMPDH, TPMT and metabolite concentrations were studied in 50 patients with IBD on stable thiopurine therapy. IMPDH activity was measured in peripheral blood mononuclear cells. TPMT activity, 6-methylthioinosine 5'-monophosphate (meTIMP) and 6-thioguanine nucleotide (6-TGN) concentrations were measured in red blood cells, which is the current practice in clinical monitoring of thiopurines. Enzyme activities were related to metabolite concentrations and clinical characteristics.
RESULTS: A wide range of IMPDH activity was observed both in healthy blood donors (median 13.1, range 4.7-24.2 nmol mg(-1) protein h(-1)) and IBD patients (median 14.0, range 7.0-21.7). There was a negative correlation between IMPDH activity and dose-normalized meTIMP concentrations (r(s) = -0.31, P = 0.03), but no evident correlation to 6-TGN concentration or the meTIMP/6-TGN ratio. There were no significant correlations between TPMT activity and metabolite concentrations.
CONCLUSION: Even though the meTIMP concentrations correlated inversely to the IMPDH activity, the role of IMPDH in balancing the formation of methylated and phosphorylated metabolites was not evident. Taken together, the results give cause to question established opinions about thiopurine metabolism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662091      PMCID: PMC2291267          DOI: 10.1111/j.1365-2125.2007.02985.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  60 in total

1.  In vitro metabolism of 6-mercaptopurine by human liver cytosol.

Authors:  K Rowland; L Lennard; J S Lilleyman
Journal:  Xenobiotica       Date:  1999-06       Impact factor: 1.908

2.  Induction of cell differentiation in melanoma cells by inhibitors of IMP dehydrogenase: altered patterns of IMP dehydrogenase expression and activity.

Authors:  K Kiguchi; F R Collart; C Henning-Chubb; E Huberman
Journal:  Cell Growth Differ       Date:  1990-06

3.  Two distinct cDNAs for human IMP dehydrogenase.

Authors:  Y Natsumeda; S Ohno; H Kawasaki; Y Konno; G Weber; K Suzuki
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

4.  Formation and significance of 6-methylthiopurine ribonucleotide as a metabolite of 6-mercaptopurine.

Authors:  L L Bennett; P W Allan
Journal:  Cancer Res       Date:  1971-02       Impact factor: 12.701

5.  Mutation in the ITPA gene predicts intolerance to azathioprine.

Authors:  A M Marinaki; J A Duley; M Arenas; A Ansari; S Sumi; C M Lewis; M Shobowale-Bakre; L D Fairbanks; J Sanderson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004-10       Impact factor: 1.381

6.  Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: results from a large Swedish patient population.

Authors:  Ulf Hindorf; Curt Peterson; Sven Almer
Journal:  Ther Drug Monit       Date:  2004-12       Impact factor: 3.681

7.  6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.

Authors:  J P Bökkerink; E H Stet; R A De Abreu; F J Damen; T W Hulscher; M A Bakker; J A van Baal
Journal:  Biochem Pharmacol       Date:  1993-04-06       Impact factor: 5.858

8.  Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity.

Authors:  Malin Lindqvist; Sofie Haglund; Sven Almer; Curt Peterson; Jan Taipalensu; Erik Hertervig; Ebbe Lyrenäs; Peter Söderkvist
Journal:  Pharmacogenetics       Date:  2004-04

9.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

10.  Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.

Authors:  C L Szumlanski; R Honchel; M C Scott; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1992-08
View more
  15 in total

1.  Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.

Authors:  Yue Zhou; Li Wang; Xiao-Ying Zhai; Li Wen; Fang Tang; Fan Yang; Xi-Ting Liu; Lei Dong; Li-Juan Zhi; Hai-Yan Shi; Guo-Xiang Hao; Yi Zheng; Evelyne Jacqz-Aigrain; Tian-You Wang; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

Review 2.  Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-03-16       Impact factor: 2.953

3.  The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.

Authors:  Hiromistu Ban; Akira Andoh; Hirotsugu Imaeda; Ayako Kobori; Shigeki Bamba; Tomoyuki Tsujikawa; Masaya Sasaki; Yasuharu Saito; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2010-10       Impact factor: 7.527

4.  Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.

Authors:  Rie Osaki; Hirotsugu Imaeda; Hiromitsu Ban; Tomoki Aomatsu; Shigeki Bamba; Tomoyuki Tsujikawa; Masaya Sasaki; Yoshihide Fujiyama; Akira Andoh
Journal:  Exp Ther Med       Date:  2011-06-16       Impact factor: 2.447

5.  New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators.

Authors:  Chamitha Weeramange; Ashabha Lansakara; Johnathan Dallman; Thi Nguyen; Wasundara Hulangamuwa; Ryan J Rafferty
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

6.  Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.

Authors:  Atinuke Aluko; Prabha Ranganathan
Journal:  Methods Mol Biol       Date:  2022

7.  NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.

Authors:  Ayumi Asada; Atsushi Nishida; Makoto Shioya; Hirotsugu Imaeda; Osamu Inatomi; Shigeki Bamba; Katsuyuki Kito; Mitsushige Sugimoto; Akira Andoh
Journal:  J Gastroenterol       Date:  2015-11-21       Impact factor: 7.527

8.  Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?

Authors:  Sofie Haglund; Sven Almer; Curt Peterson; Jan Söderman
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 9.  Monitoring and safety of azathioprine therapy in inflammatory bowel disease.

Authors:  Mi Jin Kim; Yon Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-06-30

10.  New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

Authors:  Kazuhiko Uchiyama; Tomohisa Takagi; Yasunori Iwamoto; Norihiko Kondo; Tetsuya Okayama; Naohisa Yoshida; Kazuhiro Kamada; Kazuhiro Katada; Osamu Handa; Takeshi Ishikawa; Hiroaki Yasuda; Junichi Sakagami; Hideyuki Konishi; Nobuaki Yagi; Yuji Naito; Yoshito Itoh
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.